Companies / Acrivon Therapeutics, Inc. / Activity
Activity — Acrivon Therapeutics, Inc.
27 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Millennium Management LLC 13F manager | Exit | Common Stock | $-292.9K | -122K -100.00% | 0 | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Trim | Common Stock | $-272.0K | -196K -33.44% | 389,395 0.91% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Add | Common Stock | $172.7K | +124K +19.60% | 758,440 1.77% of shares | low |
| Q1 2023 as of | Barclays PLC 13F manager | Add | Common Stock | $163.0K | +13K +310.02% | 16,983 0.04% of shares | low |
| Q1 2026 as of | Bridgeway Capital Management, LLC 13F manager | Add | Common Stock | $161.2K | +116K +270.40% | 158,900 0.37% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common Stock | $89.5K | +64K +12.97% | 560,436 1.31% of shares | low |
| Q3 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $78.9K | +11K +51.16% | 33,306 0.08% of shares | low |
| Q4 2025 as of | Bluefin Capital Management, LLC 13F manager | Exit | Common Stock | $-76.1K | -42K -100.00% | 0 | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $60.5K | +34K +16.57% | 239,112 0.56% of shares | low |
| Q1 2026 as of | Baker Bros. Advisors LP 13F manager | Exit | Common Stock | $-55.0K | -23K -100.00% | 0 | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common Stock | $53.1K | +38K +19.26% | 236,391 0.55% of shares | low |
| Q4 2023 as of | Barclays PLC 13F manager | Add | Common Stock | $51.1K | +10K +73.65% | 24,484 0.06% of shares | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | Exit | Common Stock | $-50.0K | -21K -100.00% | 0 | low |
| Q2 2023 as of | Barclays PLC 13F manager | Trim | Common Stock | $-35.3K | -3K -16.02% | 14,263 0.03% of shares | low |
| Q1 2026 as of | Prelude Capital Management, LLC 13F manager | Trim | Common Stock | $-33.4K | -24K -49.98% | 24,015 0.06% of shares | low |
| Q4 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $28.8K | +5K +14.37% | 38,091 0.09% of shares | low |
| Q1 2024 as of | Barclays PLC 13F manager | Trim | Common Stock | $-22.6K | -3K -12.91% | 21,324 0.05% of shares | low |
| Q2 2025 as of | Barclays PLC 13F manager | Trim | Common Stock | $-14.0K | -12K -36.01% | 20,925 0.05% of shares | low |
| Q1 2025 as of | Barclays PLC 13F manager | Trim | Common Stock | $-10.9K | -5K -14.16% | 32,698 0.08% of shares | low |
| Q4 2025 as of | Barclays PLC 13F manager | Add | Common Stock | $10.7K | +4K +22.22% | 24,402 0.06% of shares | low |
| Q2 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $4.1K | +709 +3.32% | 22,033 0.05% of shares | low |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Trim | Common Stock | $-3.5K | -1K -7.71% | 17,447 0.04% of shares | low |
| Q1 2026 as of | Federated Hermes Inc 13F manager | Add | Common Stock | $3.2K | +2K +41.20% | 7,924 0.02% of shares | low |
| Q3 2025 as of | Barclays PLC 13F manager | Trim | Common Stock | $-1.7K | -960 -4.59% | 19,965 0.05% of shares | low |
| Q3 2023 as of | Barclays PLC 13F manager | Trim | Common Stock | $-1.6K | -163 -1.14% | 14,100 0.03% of shares | low |
| Q1 2026 as of | Gsa Capital Partners LLP 13F manager | New | Common Stock | $260 | +187K | 186,716 0.44% of shares | low |
| Q1 2026 as of | Royal Bank of Canada 13F manager | Trim | Common Stock | $0 | -2K -98.54% | 25 <0.01% of shares | low |